Vyome Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.71next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 13 Nov 2026 |
| FY 2026 Annual Earnings Release | 18 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly8.8MTarget: Sufficient capital to fund initial Phase 3 clinical results for VT-1953
Quarterly Operating Expenses Quarterly1.1MTarget: Maintain disciplined hyper cost-efficient operational structure
Research and Development (R&D) Spend Quarterly660KTarget: Prioritize allocation toward VT-1953 pivotal-stage readiness
Watch Items
- FDA Orphan Drug Designation (ODD) approval for VT-1953Trigger: Official FDA response to the submitted ODD applicationAction: Initiate next-stage development planning and manufacturing preparedness upon approval
- FDA guidance on Phase 3 clinical trial design for VT-1953Trigger: Receipt of constructive FDA feedback on development proposalsAction: Finalize clinical protocols and commence the pivotal Phase 3 study for Malignant Fungating Wounds (MFW)
- Development progress of in-licensed JAK inhibitor assets from Impetis BiosciencesTrigger: Initiation of preclinical or clinical milestones under the capital-light structureAction: Evaluate translational data to target the broader immuno-inflammatory market
Research as of 20 Jun 2026